“We have been through a decade of intense research into treatments for rare diseases.”
Gareth Williams, partner at London-based Marks & Clerk, commenting on the patent firm’s annual life sciences report, From Rare to Routine, which found over the past decade the 10 leading pharmaceutical companies have filed a total of 8,689 patent families relating to orphan drugs

“We really do believe that leveraging our position in facial aesthetics will allow this product to grow faster, and will be bigger than it would be if Kythera were to do it on its own.”
Brent Saunders, CEO, Allergan plc, on its acquisition of Kythera Biopharmaceuticals Inc. in a cash-and-shares deal worth about $2.1 billion

“If we can actually develop a structured way to gather information from a representative sample of patients with a disease about the burden of the disease so we understand what matters to them, then we can figure ways to measure that and then figure out a way to report it back to them so they can see how they are doing with their intervention. I think this will be transformative in understanding what the medicines will and will not do. But this is a long-scale process, and we have to get it started if we are going to make this process happen.”
Janet Woodcock, director of the Center for Drug Evaluation and Research (CDER), speaking at the Develop Innovate Advance (DIA) annual meeting in Washington

“We have the potential to eliminate a viral infection from the face of earth, yet the debate is about price of a pill.”
Dana Goldman, director of the Schaeffer Center for Health Policy, during a panel at the BIO International Convention on patient access to drugs